VolitionRx announced its Nu.Q® NETs assay was selected as the sole biomarker for a €6.3 million (~$7.3 million) French government-funded project for early sepsis detection. This significant funding and validation from a major European government entity could accelerate the adoption and commercialization of VolitionRx's technology.
VolitionRx's Nu.Q® NETs assay has been chosen as the exclusive biomarker for the DETECSEPS project, a €6.3 million (~$7.3 million) French government-funded initiative aimed at the early detection of sepsis. This is a significant validation for VolitionRx's technology, providing substantial non-dilutive funding and a real-world evaluation platform in a major European healthcare system. For traders, this represents a strong positive catalyst for VNRX, as it de-risks their technology and opens doors for future commercialization and broader adoption, potentially leading to increased revenue and market share in the long term. The involvement of IHU SEPSIS and AP-HP lends considerable credibility to the project and VolitionRx's role within it.